---
title: "BTIG Remains a Buy on Humacyte (HUMA)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290615332.md"
description: "BTIG analyst Ryan Zimmerman maintained a Buy rating on Humacyte (HUMA) with a $2.00 price target, despite shares closing at $0.84. This follows a recent Buy from TD Cowen, while Piper Sandler held a Hold rating. Zimmerman, a 2-star analyst covering healthcare, has a 42.31% success rate."
datetime: "2026-06-23T21:41:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290615332.md)
  - [en](https://longbridge.com/en/news/290615332.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290615332.md)
generator: "portal-rs"
---

# BTIG Remains a Buy on Humacyte (HUMA)

BTIG analyst Ryan Zimmerman maintained a Buy rating on Humacyte yesterday and set a price target of $2.00. The company’s shares closed today at $0.84.

### TipRanks' Prime Week Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

According to TipRanks, Zimmerman is a 2-star analyst with an average return of 0.7% and a 42.31% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Glaukos, Solventum Corporation, and Intuitive Surgical.

In addition to BTIG, Humacyte also received a Buy from TD Cowen’s Josh Jennings in a report issued on June 17. However, on June 18, Piper Sandler maintained a Hold rating on Humacyte (NASDAQ: HUMA).

### Related Stocks

- [HUMA.US](https://longbridge.com/en/quote/HUMA.US.md)
- [GKOS.US](https://longbridge.com/en/quote/GKOS.US.md)
- [SOLV.US](https://longbridge.com/en/quote/SOLV.US.md)
- [ISRG.US](https://longbridge.com/en/quote/ISRG.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)
- [HUMAW.US](https://longbridge.com/en/quote/HUMAW.US.md)

## Related News & Research

- [22:00 ETHumacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA](https://longbridge.com/en/news/296662242.md)
- [Humacyte director Keith Anthony Jones reports purchase of 10,000 common shares worth $6,930](https://longbridge.com/en/news/296648477.md)
- [Humacyte says Phase 3 V007 trial results show ATEV tops fistula for hemodialysis access at one year](https://longbridge.com/en/news/296352370.md)
- [Humacyte director Keith Anthony Jones acquires 30,000 shares worth $17,820](https://longbridge.com/en/news/296394198.md)
- [Humacyte Faces Nasdaq Non-Compliance Warning as Share Price Risks Delisting and Future Capital Constraints](https://longbridge.com/en/news/295900197.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**